Singapore Hosts 2026 Cancer Breakthrough Conference

When cancer researchers from around the globe meet in Singapore from June 25-27, 2026, the conversations happening in those rooms could change the future of cancer care for millions of people.

The American Society of Clinical Oncology is bringing its ASCO Breakthrough conference to Singapore, co-hosted with the Singapore Society of Oncology. This isn't just another medical conference. It's a deliberate effort to connect the world's cancer researchers with the region that needs them most.

Asia carries 60% of the world's population but faces nearly half of all global cancer cases and 56% of cancer deaths worldwide. The numbers reveal a stark reality: breakthrough treatments developed in Western labs often take years to reach Asian patients who need them most.

Dr. Yun Yen from Taipei Medical University, who chairs the 2026 program committee, sees enormous potential. "Asia has a unique opportunity to lead in accelerating access to innovative therapies," he said. The region's genetically diverse populations and growing clinical trial capacity make it ideal for developing treatments that work for more people.

The conference expects to welcome participants from over 35 countries, building on the success of the 2024 meeting that drew nearly 800 international experts. Attendees will dive deep into major cancer types while exploring emerging priorities like early onset cancers, artificial intelligence in clinical practice, and antibody-drug conjugates.

The Ripple Effect

What makes this gathering powerful isn't just the formal presentations. It's the networking lunches where a researcher from Japan might solve a puzzle that's been stumping a team in India. It's the early-career professionals meeting mentors who open doors to collaborative studies. It's the "Women at ASCO Breakthrough" sessions building support networks that last for decades.

These behind-the-scenes conversations turn promising laboratory results into treatments that actually reach patients. A chance hallway discussion at a previous conference has led to international clinical trials. Collaborative relationships formed over coffee have accelerated drug approvals by years.

Leading ASCO experts including CEO Clifford Hudis, Chief Medical Officer Julie Gralow, and current and incoming presidents Eric Small and Elizabeth Mittendorf will be there to engage directly with attendees. The intimate conference setting creates space for the kind of deep conversations that spark real innovation.

The hope is simple: by bringing together the best minds in oncology with a dedicated focus on Asia-Pacific needs, treatments will reach patients faster and save more lives across the region and beyond.